Alphamab Oncology's (HKG:9966) investigational new drug application for JSKN027 was accepted by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.
The firm plans to initiate a phase I clinical study of JSKN027 for the treatment of advanced malignant solid tumors to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments